Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study

被引:20
|
作者
Wu, Simon [1 ,2 ]
Chee, Desmond [1 ,2 ]
Ugalde, Anna [1 ,3 ]
Butow, Phyllis [4 ]
Seymour, John [2 ,5 ]
Schofield, Penelope [1 ,2 ,6 ]
机构
[1] Peter MacCallum Canc Ctr, Dept Canc Experiences Res, East Melbourne, Vic, Australia
[2] Univ Melbourne, Fac Med Dent & Hlth Sci, Parkville, Vic 3052, Australia
[3] St Vincents Hosp Melbourne, Ctr Palliat Care, Fitzroy, Vic, Australia
[4] Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia
[5] Peter MacCallum Canc Ctr, Dept Hematol, East Melbourne, Vic, Australia
[6] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia
基金
英国医学研究理事会;
关键词
Cancer; Adherence; Chronic myeloid leukemia; Qualitative; Imatinib; DOWNWARD EVALUATION; FOLLOW-UP; COMPLEMENTARY; MEDICINE; CANCER; INTERVENTIONS; ONCOLOGISTS; REGIMENS; BEHAVIOR;
D O I
10.1017/S1478951513001260
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Consistent use of imatinib is critical for treatment success in chronic myeloid leukemia, yet perfect adherence to the prescribed clinical regimen is reported to be as low as 14%. This study aimed to understand patients' experiences of chronic myeloid leukemia with a qualitative approach, including identified facilitators and barriers to adherence, drawing on patients' and health professionals' perspectives, recording comments made by patients and health professionals involved with the same treatment team. Method: We recruited patients with chronic myeloid leukemia prescribed imatinib therapy and health professionals involved in their treatment from a specialized cancer center. Semi-structured qualitative interviews were recorded, transcribed, and manually analyzed using interpretive phenomenological analysis. Recruitment ceased upon saturation, with 16 patients and 10 health professionals (hematologists n = 4, nurses n = 3, pharmacists n = 3). Results: Twelve patients reported at least one instance of nonadherence. Reasons for unintentional nonadherence included forgetfulness related to variations of routine and doctor-patient communication issues. Reasons for intentional nonadherence included desires to reduce dose-dependent side effects and insufficient support. Patients who reported higher nonadherence rates felt complacent following periods of sustained disease control or had received conflicting advice regarding nonadherence. Health professionals had difficulty in accurately evaluating medication adherence due to a lack of reliable measures, utilizing patient self-report and manifestations of suboptimal disease control to guide assessments. Significance of Results: Adherence issues persist throughout the course of treatment. While high patient-reported nonadherence rates were recorded, health professionals were often unaware of the complex causes, compounded by an inadequacy of adherence assessment tools. Some patients reported nonadherence events because of insufficient education or lack of access to prompt medical guidance. These issues should be addressed to improve clinical practice.
引用
收藏
页码:255 / 263
页数:9
相关论文
共 50 条
  • [21] Treatment of chronic myeloid Leukemia with Imatinib IRIS-Study
    Saussele, S.
    Nitschmann, S.
    INTERNIST, 2017, 58 (11): : 1220 - 1221
  • [22] Treatment modalities in hematology: Imatinib mesylate as therapy for chronic myeloid leukemia
    A. Gratwohl
    International Journal of Hematology, 2002, 76 : 149 - 149
  • [23] Treatment modalities in hematology: Imatinib mesylate as therapy for chronic myeloid leukemia
    Gratwohl, A
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (Suppl 1) : 149 - 149
  • [24] Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib
    Unnikrishnan, Radhika
    Veeraiah, Surendran
    Mani, Samson
    Rajendranath, Rejiv
    Rajaraman, Swaminathan
    Elangovan, Grace Sahaya Vidhubala
    Radhakrishnan, Venkatraman
    Ganesan, Trivadi S.
    Sagar, Tenali G.
    Ganesan, Prasanth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (06): : 366 - +
  • [25] Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study
    Kapoor, Jyotsna
    Agrawal, Narendra
    Ahmed, Rayaz
    Sharma, Sanjeev Kumar
    Gupta, Anshul
    Bhurani, Dinesh
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2015, 7
  • [26] Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy
    Proschmann, Rick
    Baldow, Christoph
    Rothe, Tino
    Suttorp, Meinolf
    Thiede, Christian
    Tauer, Josephine T.
    Mfiller, Martin C.
    Hochhaus, Andreas
    Roeder, Ingo
    Glauche, Ingmar
    HAEMATOLOGICA, 2017, 102 (02) : E39 - E42
  • [27] Semen analysis during imatinib therapy in patients with chronic myeloid leukemia
    Maloisel, F.
    Zamfir, A.
    Bennada, K.
    Clavert, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 201 - 201
  • [28] COMPLETE MOLECULAR RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON IMATINIB THERAPY
    Aksenova, E.
    Chelysheva, E.
    Krutov, A.
    Soldatova, I.
    Misiurin, A.
    Vinogradova, O.
    Gusarova, G.
    Zakharova, E.
    Sokolova, M.
    Nemchenko, I.
    Kuznetsov, S.
    Lazareva, O.
    Vorontsova, A.
    Kolosheinova, T.
    Kolosova, L.
    Goryacheva, S.
    Ivanova, T.
    Turkina, A.
    Khoroshko, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 346 - 346
  • [29] Long Term Adherence to Imatinib Therapy is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients
    Bazeos, Alex
    Khorashad, Jamshid
    Mahon, Francois-Xavier
    Eliasson, Lina L.
    Milojkovic, Dragana
    Bua, Marco
    Apperley, Jane
    Szydlo, Richard
    Kozlowski, Kasia
    Paliompeis, Christos
    Desai, Ritti
    Foroni, Letizia
    Reid, Alistair
    de Lavallade, Hugues
    Rezvani, Katy
    Goldman, John
    Marin, David
    BLOOD, 2009, 114 (22) : 1274 - 1275
  • [30] Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy
    Efficace, Fabio
    Baccarani, Michele
    Breccia, Massimo
    Alimena, Giuliana
    Rosti, Gianantonio
    Cottone, Francesco
    Castagnetti, Fausto
    Deliliers, Giorgio Lambertenghi
    Rossi, Antonella Russo
    Pardini, Simonetta
    Gherlinzoni, Filippo
    Salvucci, Marzia
    Tiribelli, Mario
    Vignetti, Marco
    Mandelli, Franco
    BLOOD, 2011, 118 (21) : 471 - 471